All In Biotech

Drug Trial Radar · NCT04776499

Possible Effects of Propylthiouracil, Riociguat and Perphenazine on Circulation of Healthy Volunteers

Clinical Evaluation in Healthy Volunteers of Potential syneRgistic Vascular Effects of PrOpylthiouracil, Riociguat, and Perphenazine a Possible STROKE Medication

Last checked: Nov 20, 2026Latest source record: Apr 4, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

8

Actual

Start

Mar 18, 2021

Primary completion

Feb 28, 2022

Study completion Feb 28, 2022

Sponsor

Lead sponsor
Maastricht UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
European Commission
First posted
Mar 1, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Other
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 64 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This trial is part of the Horizon 2020 project, REPO-TRIAL, on in-silico, mechanism-based drug repurposing in high unmet-medical-need indications. This project aims to identify causal, rather than symptomatic disease mechanisms for highly precise and effective interventions. Here a signalling module comprised of reactive oxygen species (ROS) formation and cyclic GMP signalling has been identified to be involved in post-stroke blood-brain-barrier disruption and neuronal death. It can be targeted by repurposing three drugs, which inhibit overshooting nitric oxide (NO) and ROS formation, respectively, and stimulate compromised neuroprotective cyclic GMP formation. It is possible that two of the drugs (riociguat, perphenazine) may cause a drop and one drug an elevation of blood pressure (propylthiouracil) leading to an overall drop in blood pressure. On top of that, the three drugs may synergise on blood pressure in a previously not recognised manner. These potential safety concerns, expressed in a scientific advice meeting by the Federal Institute for Drugs and Medical Devices (BfArM), shall be tested in the present phase I safety trial. The trial consists of a screening visit (SCR), a treatment period, and an EOT visit. In the treatment period, after a baseline evaluation, single doses of all three substances will be administered concurrently. Provocation manoeuvres (tilt table) will be performed with the goal of generating maximum safety information on drug-induced blood pressure changes. Concurrently, a 24-h electrocardiogram (ECG) will be recorded (Holter ECG) and blood samples will be drawn for exploratory biomarker analyses, quantification of riociguat, and optional pharmacokinetic analyses of perphenazine and propylthiouracil.

Conditions

  • Drug Drug Interaction
  • Safety Issues

Interventions

  • Propylthiouracil, Riociguat, PerphenazineDrug

    Administration of propylthiouracil, riociguat, and perphenazine in combination Investigational medicinal product (IMP): Propylthiouracil: 100 mg, Riociguat: 1 mg, Perphenazine: 16 mg

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change of blood pressure in supine positionTime frame: 0.25, 0.5, 0.75, 1.0, 1.5, 2, 3 and 4 hours after drug administration compared to baseline (measured in triplicate 1-2 minutes apart)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • UniversitätsKlinikum Heidelberg - Medizinische Klinik

    Heidelberg, Germany

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.